Heidelberg Pharma Receives Milestone Payment from Takeda as ATAC-Based ADC Enters Phase I/II Trial
核心洞察
Heidelberg Pharma (搜索) received a milestone payment from Takeda (搜索) following the dosing of the first patient in a Phase I/II clinical trial for an ADC utilizing ATAC technology.
Three ATAC-based candidates are now in clinical development, including two proprietary programs at Heidelberg Pharma (搜索) and one with Takeda (搜索).
The milestone represents validation of Heidelberg Pharma (搜索)'s unique Amanitin-based ADC technology derived from the death cap mushroom.
Heidelberg Pharma (搜索) AG announced it has received a milestone payment from Japanese pharmaceutical giant Takeda (搜索) following the initiation of a Phase I/II clinical trial for an investigational ADC that utilizes the company's proprietary ATAC technology. The milestone was triggered by the dosing of the first patient in the solid tumor study, though financial details of the payment were not disclosed.
The development marks a significant step forward for Heidelberg Pharma (搜索)'s Amanitin-based Antibody Drug Conjugate technology, which represents the first use of compounds from the green death cap mushroom in cancer therapy. Dr. Dongzhou Jeffery Liu, Chief Executive Officer of Heidelberg Pharma, expressed satisfaction with the progress, stating: "We are very delighted that our partner Takeda (搜索) is progressing the development of their investigational medicine that utilizes ATAC technology, and that we have received the according milestone payment."
ATAC Technology Gains Clinical Momentum
With Takeda (搜索)'s candidate now in clinical development, three ATAC-based programs are currently being evaluated in human trials. Heidelberg Pharma (搜索) maintains two proprietary candidates: HDP-101 (pamlectabart tismanitin (搜索)), a BCMA (搜索) ATAC in development for multiple myeloma (搜索) that has received both Orphan Drug Designation and Fast Track Designation from the FDA, and HDP-102, which is being studied in Non-Hodgkin Lymphoma (搜索).
The ATAC technology platform combines the specificity of antibodies with cytotoxic compounds derived from Amanitin, creating a novel therapeutic modality. According to the company, dosing patients with the ADC and the mushroom-derived toxin has proven highly promising, with relatively high concentrations achieved without severe side effects. Complete remissions have been observed in two out of four patients in early studies.
Partnership Details and Pipeline Progress
Under the licensing agreement with Takeda (搜索), the Japanese company holds exclusive worldwide development and commercialization rights for an ATAC-based product candidate targeting a specific, undisclosed target. Takeda assumes full responsibility for clinical development and potential commercialization of the resulting product candidate.
Beyond the active clinical programs, Heidelberg Pharma (搜索) has completed preclinical development of two additional ATAC candidates: HDP-103 for metastatic castration-resistant prostate cancer (搜索) and HDP-104 targeting gastrointestinal tumors including colorectal cancer (搜索).
Recovery from Operational Challenges
The milestone payment provides welcome momentum for Heidelberg Pharma (搜索) following a challenging period that included job cuts, restructuring, pipeline narrowing, and leadership changes. The company had been awaiting this development milestone while also expecting a separate, potentially larger milestone payment from Australian partner Telix (搜索) related to FDA approval of a renal cancer (搜索) diagnostic originally developed by Munich-based Wilex AG.
Liu noted that the current progress represents "a further validation of the potential of our unique Amanitin-based ADC technology." The company, based in Ladenburg, Germany, continues to seek partnerships for its expanding ATAC technology platform as it advances multiple candidates through clinical development.